Altium Capital Management LP Cyma Bay Therapeutics, Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $8.7 Million - $16.9 Million	-689,000 Reduced 86.13%	111,000 $2.62 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $1.43 Million - $2.31 Million	131,298 Added 19.63%	800,000 $11.9 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $363,803 - $533,286	48,702 Added 7.86%	668,702 $7.32 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $2.38 Million - $3.88 Million	-405,000 Reduced 39.51%	620,000 $5.41 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $6.27 $2.33 Million - $4.55 Million	-725,000 Reduced 41.43%	1,025,000 $6.43 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $5.65 Million - $8.05 Million	1,750,000 New	1,750,000 $5.92 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.